|
|
Article: HemoBioTech Chairman and CEO, Dr. Arthur Bollon, to Give Update Tomorrow in Dallas on the Company and Development of Its Artificial Blood Product, HemoTech.
- Article from:
- Business Wire
- Article date:
- July 31, 2007
CopyrightCOPYRIGHT 2007 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Presentation will be at the Tower Club, Thanksgiving Tower, 1601 Elm Street, 48th Floor, Dallas
DALLAS -- HemoBioTech (OTCBB: HMBT.OB) announced that its Chairman and CEO, Arthur Bollon, Ph.D., will give a luncheon presentation tomorrow (Wednesday, Aug. 1st) at the Tower Club (www.towerclub.com), Thanksgiving Tower, 1601 Elm Street, 48th Floor, Dallas. Please call WaLisa Davenport Satcher at 972-455-8953 for further information.
HemoBioTech is developing what could be the world's first viable substitute for human blood--HemoTech--exclusively licensed from Texas Tech University Health Sciences Center. Previous efforts by other companies to develop a human ...